We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nabi Biopharmaceuticals has received orphan medicinal product (OMP) designation
from the European Commission for Civacir, the company's product candidate for
the prevention of recurrent hepatitis C virus-induced liver disease in liver
transplant recipients.
It is not uncommon for patients with autoimmune hepatitis (AIH), a disease in
which the patient's own immune system attacks the liver, to have no symptoms.
Generex Biotechnology has signed a research collaboration agreement with Stallergenes,
a European firm developing immunological treatments for allergy and asthma.
Arena Pharmaceuticals has started dosing patients in a Phase IIb clinical trial
of APD356, an orally administered, internally discovered drug candidate for
the treatment of obesity.
VIVUS has announced positive results from a Phase II study to evaluate the effects
of Avanafil, its investigational oral phosphodiesterase type 5 (PDE5) inhibitor,
in men with erectile dysfunction (ED).
Stressgen Biotechnologies has completed the manufacture of HspE7, which will
allow for the release of HspE7 for use in the a Phase III clinical study in
recurrent respiratory papillomatosis (RRP).
Join FDAnews Tuesday, June 28 for "Dietary Supplement Safety: Meet
FDA's Latest Standards, Minimize Product Liabilities." Protect your bottom
line as you discover how to overcome the latest legal and compliance obstacles
facing your industry from a three-member team of experts. On July 14, join FDAnews
for "Accelerate Clinical Trial Enrollment: Performance Metrics for Recruiting
Subjects on Time and on Budget." Learn from a pro on how to populate your
studies, achieve spectacular results for your site- and study-specific needs,
and optimize your financial, time and personnel resources.